Subject Review: Pancreatic Ductal Adenocarcinoma in the Setting of Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator Gene: Case Report and Review of the Literature

David W. Rittenhouse, Vanessa A. Talbott, Zafia Anklesaria, Jonathan R. Brody, Agneszkia K. Witkiewicz, Charles J. Yeo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Cystic fibrosis (CF) is the most commonly inherited lethal autosomal recessive genetic disease amongst Caucasians. CF results from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Patients with homozygous or compound heterozygous CFTR mutations have a risk of pancreatitis, but typically do not live long enough to develop pancreatic ductal adenocarcinoma (PDA), a disease that has an average age at diagnosis of 65 years. Little is known about the risk of the development of PDA in people who are heterozygous for mutations in the CFTR gene. Patients and Methods: We report a case of a patient with PDA who underwent resection, who is a carrier for the W1282X nonsense mutation in the CFTR gene. The patient is of Ashkenazi Jewish ethnicity and has a family history of CF, but no family history of PDA. We reviewed the English language literature for the prevalence of PDA in CF patients (and CFTR mutations in the setting of PDA) and their significance in terms of screening, and the use of this mutation as a biomarker for an increased risk of the development of PDA. Conclusion: We conclude that patients with CFTR mutations, who also have other risks for the development of PDA such as a family history of the disease, should undergo screening and be educated about their risks.

Original languageEnglish (US)
Pages (from-to)2284-2290
Number of pages7
JournalJournal of Gastrointestinal Surgery
Volume15
Issue number12
DOIs
StatePublished - Dec 2011

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
Regulator Genes
Adenocarcinoma
Mutation
Cystic Fibrosis
Inborn Genetic Diseases
Nonsense Codon
Pancreatitis
Language
Biomarkers

Keywords

  • Cystic fibrosis
  • Pancreatic ductal adenocarcinoma
  • W1282X mutation

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Subject Review : Pancreatic Ductal Adenocarcinoma in the Setting of Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator Gene: Case Report and Review of the Literature. / Rittenhouse, David W.; Talbott, Vanessa A.; Anklesaria, Zafia; Brody, Jonathan R.; Witkiewicz, Agneszkia K.; Yeo, Charles J.

In: Journal of Gastrointestinal Surgery, Vol. 15, No. 12, 12.2011, p. 2284-2290.

Research output: Contribution to journalArticle

@article{86f3ea8077f54774b30c954798ca621e,
title = "Subject Review: Pancreatic Ductal Adenocarcinoma in the Setting of Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator Gene: Case Report and Review of the Literature",
abstract = "Background: Cystic fibrosis (CF) is the most commonly inherited lethal autosomal recessive genetic disease amongst Caucasians. CF results from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Patients with homozygous or compound heterozygous CFTR mutations have a risk of pancreatitis, but typically do not live long enough to develop pancreatic ductal adenocarcinoma (PDA), a disease that has an average age at diagnosis of 65 years. Little is known about the risk of the development of PDA in people who are heterozygous for mutations in the CFTR gene. Patients and Methods: We report a case of a patient with PDA who underwent resection, who is a carrier for the W1282X nonsense mutation in the CFTR gene. The patient is of Ashkenazi Jewish ethnicity and has a family history of CF, but no family history of PDA. We reviewed the English language literature for the prevalence of PDA in CF patients (and CFTR mutations in the setting of PDA) and their significance in terms of screening, and the use of this mutation as a biomarker for an increased risk of the development of PDA. Conclusion: We conclude that patients with CFTR mutations, who also have other risks for the development of PDA such as a family history of the disease, should undergo screening and be educated about their risks.",
keywords = "Cystic fibrosis, Pancreatic ductal adenocarcinoma, W1282X mutation",
author = "Rittenhouse, {David W.} and Talbott, {Vanessa A.} and Zafia Anklesaria and Brody, {Jonathan R.} and Witkiewicz, {Agneszkia K.} and Yeo, {Charles J.}",
year = "2011",
month = "12",
doi = "10.1007/s11605-011-1639-y",
language = "English (US)",
volume = "15",
pages = "2284--2290",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Subject Review

T2 - Pancreatic Ductal Adenocarcinoma in the Setting of Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator Gene: Case Report and Review of the Literature

AU - Rittenhouse, David W.

AU - Talbott, Vanessa A.

AU - Anklesaria, Zafia

AU - Brody, Jonathan R.

AU - Witkiewicz, Agneszkia K.

AU - Yeo, Charles J.

PY - 2011/12

Y1 - 2011/12

N2 - Background: Cystic fibrosis (CF) is the most commonly inherited lethal autosomal recessive genetic disease amongst Caucasians. CF results from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Patients with homozygous or compound heterozygous CFTR mutations have a risk of pancreatitis, but typically do not live long enough to develop pancreatic ductal adenocarcinoma (PDA), a disease that has an average age at diagnosis of 65 years. Little is known about the risk of the development of PDA in people who are heterozygous for mutations in the CFTR gene. Patients and Methods: We report a case of a patient with PDA who underwent resection, who is a carrier for the W1282X nonsense mutation in the CFTR gene. The patient is of Ashkenazi Jewish ethnicity and has a family history of CF, but no family history of PDA. We reviewed the English language literature for the prevalence of PDA in CF patients (and CFTR mutations in the setting of PDA) and their significance in terms of screening, and the use of this mutation as a biomarker for an increased risk of the development of PDA. Conclusion: We conclude that patients with CFTR mutations, who also have other risks for the development of PDA such as a family history of the disease, should undergo screening and be educated about their risks.

AB - Background: Cystic fibrosis (CF) is the most commonly inherited lethal autosomal recessive genetic disease amongst Caucasians. CF results from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Patients with homozygous or compound heterozygous CFTR mutations have a risk of pancreatitis, but typically do not live long enough to develop pancreatic ductal adenocarcinoma (PDA), a disease that has an average age at diagnosis of 65 years. Little is known about the risk of the development of PDA in people who are heterozygous for mutations in the CFTR gene. Patients and Methods: We report a case of a patient with PDA who underwent resection, who is a carrier for the W1282X nonsense mutation in the CFTR gene. The patient is of Ashkenazi Jewish ethnicity and has a family history of CF, but no family history of PDA. We reviewed the English language literature for the prevalence of PDA in CF patients (and CFTR mutations in the setting of PDA) and their significance in terms of screening, and the use of this mutation as a biomarker for an increased risk of the development of PDA. Conclusion: We conclude that patients with CFTR mutations, who also have other risks for the development of PDA such as a family history of the disease, should undergo screening and be educated about their risks.

KW - Cystic fibrosis

KW - Pancreatic ductal adenocarcinoma

KW - W1282X mutation

UR - http://www.scopus.com/inward/record.url?scp=81355138696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81355138696&partnerID=8YFLogxK

U2 - 10.1007/s11605-011-1639-y

DO - 10.1007/s11605-011-1639-y

M3 - Article

C2 - 21809164

AN - SCOPUS:81355138696

VL - 15

SP - 2284

EP - 2290

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 12

ER -